Turn Therapeutics Inc. TTRX
Set alert
10.43 USD -0.29 -2.71%
At close · Oct 30
10.65 +0.22 +2.11%
After hours · Oct 30, 5:33 PM ET
9.60 Day range 10.54
2.71 52-week range 15.34
- YTD
- +164.72%
- 1 year
- +99.05%
- Open
- 10.45
- Prev close
- 10.72
- Mkt cap
- 316.74M
- Vol
- 137.07K
- Avg vol
- 105.53K
- EPS
- -0.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.60
- High
- 10.54
3M chart
Signals (8)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| RSI: Overbought | Sep 16, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Financials — quick view
TTRX Revenue — quarterly 0
TTRX Net income — quarterly -5.85M
TTRX EPS — quarterly -0.20
News
- This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
- This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
- WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10
- U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
- This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
- WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
- Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.
Your note
Sign in to keep a note on TTRX — it syncs with the Stock Master app.